Decreased levels of soluble receptor for advanced glycation end-products in aortic valve calcification patients

Abstract

ABSTRACT. The soluble receptor for advanced glycation endproducts (sRAGE) shows a close relationship with atherosclerosis. The goal of this study was to compare the levels of sRAGE in patients with and without aortic valve calcification and to investigate the relationship between them. After transthoracic echocardiographic examination, 120 male patients with aortic valve calcification and 120 age-matched male controls without aortic valve calcification were included in our study. sRAGE levels were compared between groups. The prevalence of diabetes mellitus and coronary artery disease were significantly higher in the aortic valve calcification group than in the control group (63.3 versus 45%, P = 0.01, and 65 versus 51.7%, P < 0.01, respectively). The levels of sRAGE were lower in the aortic valve calcification group than in the control group (203.8 ± 34.6 versus 324.7 ± 41.6 pg/mL, H. Zheng et al. 3776©FUNPEC-RP www.funpecrp.com.br Genetics and Molecular Research 14 (2): 3775-3783 (2015) P < 0.01). In multivariate analysis, age, coronary artery disease, and sRAGE levels were independent predictors of aortic valve calcification. Our study demonstrates that sRAGE, which was proven to be a potential marker of atherosclerosis, might have a role in the development of aortic valve calcification.

Damaging effects of hyperglycemia on cardiovascular function: spotlight on glucose metabolic pathways

“…For example, serum sRAGE levels are inde-pendently correlated with a marker of central aortic stiffness, therefore suggesting a potential role for RAGE in this process (260,335). Other researchers have found that sRAGE is a predictor of aortic valve calcification (346) and correlates with dysfunctional aortic microstructure (33). It is also an inverse marker of left ventricular hypertrophy in patients with chronic kidney disease, therefore indicating that the RAGE pathway may be a causal risk factor for cardiac hypertrophy in this instance (174).…”